Biokin Pharmaceutical is a comprehensive biopharmaceutical enterprise focusing on cutting‑edge global biomedicine. Dedicated to addressing unmet clinical needs, it boasts capabilities in global early‑stage R&D, worldwide clinical development, large‑scale manufacturing and commercialization. Guided by its strategic positioning of  “Rooted in China, Going Global, Becoming a Multinational Pharmaceutical Company (MPC)”, the Company has long adhered to the R&D and innovation philosophy of “Science‑based, Frontier‑pursuing, and Data‑driven”. It is committed to delivering breakthrough‑efficacy innovative oncology drugs for patients worldwide and growing into a globally leading MNC in the field of oncology therapeutics.

The Company operates R&D centers in both China and the United States: the SystImmune R&D Center in Seattle, the USA and Baili Pharmaceutical/Baili-Bio R&D Center in Chengdu, Sichuan Province, China. Through close and efficient collaboration between the dual‑site R&D hubs, a full‑chain drug innovation system has been fully established, covering “0‑to‑1” breakthroughs that generate novel therapeutic concepts, as well as accelerated “1‑to‑N” clinical translation and development. This continuously consolidates our innovation capacity and efficiency advantages in global pharmaceutical R&D.